Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial

Background CombiRx was a randomized, double-blind, placebo-controlled phase 3 trial in treatment-naive relapsing-remitting multiple sclerosis (RRMS) patients randomized to intramuscular interferon beta-1a (IM IFN beta-1a), glatiramer acetate (GA), or both therapies. Objective This analysis investiga...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Gary Cutter, Richard A Rudick, Carl de Moor, Carol M Singh, Elizabeth Fisher, Thijs Koster, Fred D Lublin, Jerry S Wolinsky, Henry McFarland, Steven Jacobson, Maria L Naylor
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	SAGE Publishing 2023-04-01
Serie:	Multiple Sclerosis Journal - Experimental, Translational and Clinical
Accesso online:	https://doi.org/10.1177/20552173231169463
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!